Employee image

Dr. Sigrid Carlsson

Head of Division

Division Head
 

Research focus

Risk-adapted prostate cancer screening
Screening & Early detection
Clinical epidemiology
Medical decision making

Studies and projects

European Randomized Study of Screening for Prostate Cancer (ERSPC)
Organized Prostate cancer Testing (OPT) Sweden
PCBase Xtend Sweden
EU4Health PRAISE-U
EU EIC PATHFINDER PROMETHEUS
Prostate Cancer Foundation
Pro-Quant-AI
Salpingectomy for Prevention of Ovarian cancer Trial (SPOT)
German National Cohort (NAKO)

Other activities and memberships

Adjunct Senior Lecturer, Department of Translational Medicine, Division of Urological Cancers, Lund University, Lund, Sweden
Managing Directorate, National Cancer Prevention Center (NCPC), DKFZ
International Alliance for Cancer Early Detection (ACED) (Deputy Director for DKFZ)
Deutsches Konsortium für Translationale Krebsforschung (DKTK), DKFZ
Netzwerk Altersforschung (NAR), Board of Directors
EU4Health PRAISE-U, Scientific Advisory Board member and Collaborator
American Cancer Society, Early detection of prostate cancer guideline panel member
American Urological Association/Society of Urologic Oncology (AUA/SUO) Early detection of prostate cancer guideline member
BJU International, Statistical editor
Scientific programme committee for:
ICCP: 5th International Conference on Cancer Prevention (19-October 21, 2026): Overview · DKFZ Event Managment System (Indico)
EDx conference: The Early Detection of Cancer Conference – 6-8 October 2026, Edinburgh, UK

Current doctoral students, postdocs and clinican scientists

Incoming PhD student 2026
Ya Zhang
Dmitry Sergeev
Fabian Falkenbach
Caelan Haney 

Publications

Articles in PubMed

ORCID profile


Selected publications from recent years

Albers P, Carlsson S, Krilaviciute A, Seibold P, Becker N. The Proposed Introduction of a Prostate Cancer Screening Program in Germany: Procedure, Necessary Studies before Implementation, Benefits, and Risks. Dtsch Arztebl Int. 2026 May 29;123(11):arztebl.m2026.0040. doi: 10.3238/arztebl.m2026.0040. 

Padhani AR, Carlsson S, Bratt O, Schoots IG. Introducing Key Performance Metrics for Assessing the Benefits and Harm of the Prostate Cancer Diagnostic Pathway. Eur Urol Oncol. 2026 Mar 17:S2588-9311(26)00061-1. doi: 10.1016/j.euo.2026.03.002

Lin DW, Carlsson S, Filson CP, Kim SK, Kirkby E, Konety BR, Purysko AS, Souter LH. Updates to Early Detection of Prostate Cancer: AUA/SUO Guideline (2026). J Urol. 2026 May;215(5):491-501. doi: 10.1097/JU.0000000000004995. 

Carlsson SV, Krilaviciute A, Al-Monajjed R, Seibold P, Kuczyk M, Gschwend JE, Debus J, Antoch G, Schimmöller L, Schlemmer HP, Kristiansen G, Kaaks R, Becker N, Albers P; PROBASE Study Group. Risk-adapted Prostate Cancer Screening Achieves Mammography-like Benefits: Evidence and Implications for Europe. Eur Urol. 2026 Mar;89(3):193-195. doi: 10.1016/j.eururo.2025.12.002.

Roobol MJ, de Vos II, Månsson M, Godtman RA, Talala KM, den Hond E, Nelen V, Villers A, Poinas G, Kwiatkowski M, Wyler S, Recker F, Puliti D, Gorini G, Zappa M, Paez A, Lujan M, Bangma CH, Tammela T, Schröder FH, Remmers S, Hugosson J, Auvinen A; ERSPC Investigators. European Study of Prostate Cancer Screening - 23-Year Follow-up. N Engl J Med. 2025 Oct 30;393(17):1669-1680. doi: 10.1056/NEJMoa2503223. 

Vertosick EA, Vickers A, Dahlin A, Ulmert D, Carlsson SV, Eastham J, Bjartell A, Lilja H. Prostate-specific antigen levels at age 60 years and lifetime risk of lethal prostate cancer. J Natl Cancer Inst. 2025 Dec 1;117(12):2591-2597. doi: 10.1093/jnci/djaf271

Garraway IP, Carlsson SV, Nyame YA, Vassy JL, Chilov M, Fleming M, Frencher SK, George DJ, Kibel AS, King SA, Kittles R, Mahal BA, Pettaway CA, Rebbeck T, Rose B, Vince R, Winn RA, Yamoah K, Oh WK. Prostate Cancer Foundation Screening Guidelines for Black Men in the United States. NEJM Evid. 2024 May;3(5):EVIDoa2300289. doi: 10.1056/EVIDoa2300289

Josefsson A, Månsson M, Kohestani K, Spyratou V, Wallström J, Hellström M, Lilja H, Vickers A, Carlsson SV, Godtman R, Hugosson J. Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in the GÖTEBORG-2 Prostate Cancer Screening Trial. Eur Urol. 2024 Sep;86(3):223-229. doi: 10.1016/j.eururo.2024.04.037.

Bjerner J, Bratt O, Aas K, Albertsen PC, Fosså SD, Kvåle R, Lilja H, Müller C, Müller S, Stensvold A, Thomas O, Røe OD, Vickers A, Walz J, Carlsson SV, Oldenburg J. Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death-Results from the Norwegian Prostate Cancer Consortium. Eur Urol. 2024 Jul;86(1):20-26. doi: 10.1016/j.eururo.2023.04.028. 

Hugosson J, Månsson M, Wallström J, Axcrona U, Carlsson SV, Egevad L, Geterud K, Khatami A, Kohestani K, Pihl CG, Socratous A, Stranne J, Godtman RA, Hellström M; GÖTEBORG-2 Trial Investigators. Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only. N Engl J Med. 2022 Dec 8;387(23):2126-2137. doi: 10.1056/NEJMoa2209454.

Form

Form data is loaded ...